Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271533 | 0.87 | GPR119 (0.52) | GPR119TRPA1GRM2CYP2C9CYP1A2 | |
| SCHEMBL10116289 | 0.87 | GPR119 (0.40) | GPR119GRM2CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL10116316 | 0.77 | GPR119 (0.43) | GPR119CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL12271277 | 0.73 | S1PR1 (0.45) | GPR119GRM2CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL10116293 | 0.73 | TRPA1 (0.39) | GPR119TRPA1CYP2C9 | |
| SCHEMBL12276341 | 0.73 | GPR119 (0.50) | GPR119TRPA1CYP2C9 | |
| SCHEMBL10116292 | 0.72 | GPR119 (0.55) | GPR119TRPA1CYP2C9 | |
| SCHEMBL11993142 | 0.71 | KDM4E (0.42) | GPR119CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10105723 | 0.70 | GPR119 (0.38) | GPR119GRM2CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL12271284 | 0.70 | GPR119 (0.47) | GPR119CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | GPR119 1/4885TRPA1 84/4885GRM2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.